Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

By B. Cheson, P. Greenberg, J. Bennett, B. Lowenberg, P. Wijermans, S. Nimer, A. Pinto, M. Beran, T. D. de Witte, R. Stone and 5 more. Blood, 2006

1,591 citations recorded by the source corpus.

Subfields: Hematology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/028c0b88440cb04d43cb3805a2cde37fdae0131a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. L. Malcovati
2. E. Hellström-Lindberg
3. D. Bowen
4. U. Germing
5. J. Čermák
6. G. Sanz
7. L. Adès
8. P. Fenaux

Citations in the corpus

• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. (2007, neutral): “Median number of courses (range) 5 (1-18) 8 (1-17) 9 (1-15)”
• Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. (2013, methodology): “Standardized response criteria inMDS were defined by the International Working Group (IWG) in 2000(114) and revised in 2006.(115) The IWG criteria define different aspects of responses on the basis of treatment goals: complete or partial remission and cytogenetic response for treatments altering the”
• TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes (2016, neutral): “With incomplete count recovery 24 (21) 9 (43) 15 (19) 0 0.”